39 related articles for article (PubMed ID: 2058066)
1. Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12.
Zaharoff DA; Hoffman BS; Hooper HB; Benjamin CJ; Khurana KK; Hance KW; Rogers CJ; Pinto PA; Schlom J; Greiner JW
Cancer Res; 2009 Aug; 69(15):6192-9. PubMed ID: 19638573
[TBL] [Abstract][Full Text] [Related]
2. An aid to a better understanding of the definitions of BCG failure provided by the European Urology Association.
Pérez JH; Faba OR; Gaya Sopena JM; Palou Redorta J; Breda A
Actas Urol Esp (Engl Ed); 2023 Sep; 47(7):395-397. PubMed ID: 36842705
[No Abstract] [Full Text] [Related]
3. RETRACTED: Schizandrin A enhances chemosensitivity of colon carcinoma cells to 5-fluorouracil through up-regulation of miR-195.
Kong D; Zhang D; Chu X; Wang J
Biomed Pharmacother; 2018 Mar; 99():176-183. PubMed ID: 29331856
[TBL] [Abstract][Full Text] [Related]
4. LncRNA SNHG12 regulates gastric cancer progression by acting as a molecular sponge of miR‑320.
Zhang H; Lu W
Mol Med Rep; 2018 Feb; 17(2):2743-2749. PubMed ID: 29207106
[TBL] [Abstract][Full Text] [Related]
5. Different smoking risks of flue-cured and air-cured tobaccos.
Passey RD; Elson LA
J Pathol; 1970 Aug; 101(4):P18. PubMed ID: 5504722
[No Abstract] [Full Text] [Related]
6. Immune therapies in non-muscle invasive bladder cancer.
Ho PL; Williams SB; Kamat AM
Curr Treat Options Oncol; 2015 Feb; 16(2):5. PubMed ID: 25757877
[TBL] [Abstract][Full Text] [Related]
7. Emerging intravesical therapies for management of nonmuscle invasive bladder cancer.
Tomaszewski JJ; Smaldone MC
Open Access J Urol; 2010 May; 2():67-84. PubMed ID: 24198616
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of bladder cancer.
Nseyo UO; Lamm DL
Semin Surg Oncol; 1997; 13(5):342-9. PubMed ID: 9259090
[TBL] [Abstract][Full Text] [Related]
9. [Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study].
Kälble T; Möhring K; Ikinger U; Riedasch G; Staehler G
Urologe A; 1991 Mar; 30(2):118-21. PubMed ID: 2058066
[TBL] [Abstract][Full Text] [Related]
10. [Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study].
Flamm J; Donner G; Bucher A; Höltl W; Albrecht W; Havelec L
Urologe A; 1994 Mar; 33(2):138-43. PubMed ID: 8178408
[TBL] [Abstract][Full Text] [Related]
11. [BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study].
Kälble T; Beer M; Mendoza E; Ikinger U; Link M; Reichert HE; Frangenheim T; Klein E; Fabricius PG
Urologe A; 1994 Mar; 33(2):133-7. PubMed ID: 8178407
[TBL] [Abstract][Full Text] [Related]
12. [Unconventional therapeutic methods in superficial bladder cancer].
Kälble T; Otto T
Urologe A; 1994 Nov; 33(6):553-6. PubMed ID: 7817456
[TBL] [Abstract][Full Text] [Related]
13. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
[TBL] [Abstract][Full Text] [Related]
14. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
